Breaking News Instant updates and real-time market news.

2021-03-04 16:44:22 CLLS Cellectis $19.29 / -0.9 (-4.46%) 16:44 03/04/21 03/04 16:44 03/04/21 16:44	Cellectis reports Q4 adjusted EPS (88c), consensus (78c) Reports Q4 revenue $16M, consensus $7.64M. "2020 was a challenging but very fruitful year for Cellectis," said Dr. Andre Choulika, Chief Executive Officer of Cellectis. "We moved forward with our three Cellectis-sponsored clinical studies, and shared preliminary results for our BALLI-01 study at ASH. AMELI-01 for the treatment of relapsed or refractory acute myeloid lymphomia (r/r AML) and BALLI-01 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) are enrolling patients at dose level 2 with FCA (fludarabine, cyclophosphamide and alemtuzumab) lymphodepletion regimen. Our MELANI-01 clinical study for patients with relapsed or refractory multiple myeloma (r/r MM) has restarted patient enrollment. We are planning to share selected updated interim data in 2021."	05 Mar 16 Dec
CLLS Cellectis $19.29 / -0.9 (-4.46%) 10/15/20 Baird Cellectis downgraded to Neutral at Baird 10/15/20 Baird Cellectis downgraded to Neutral from Outperform at Baird 08/19/20 Fly Intel: Top five analyst upgrades 08/19/20 Citi Cellectis upgraded to Buy from Neutral at Citi

2021-03-04 16:44:22

CLLS

Cellectis

$19.29 / -0.9 (-4.46%)

16:44

03/04/21

03/04

16:44

03/04/21

16:44

Cellectis reports Q4 adjusted EPS (88c), consensus (78c)

Reports Q4 revenue $16M, consensus $7.64M. "2020 was a challenging but very fruitful year for Cellectis," said Dr. Andre Choulika, Chief Executive Officer of Cellectis. "We moved forward with our three Cellectis-sponsored clinical studies, and shared preliminary results for our BALLI-01 study at ASH. AMELI-01 for the treatment of relapsed or refractory acute myeloid lymphomia (r/r AML) and BALLI-01 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) are enrolling patients at dose level 2 with FCA (fludarabine, cyclophosphamide and alemtuzumab) lymphodepletion regimen. Our MELANI-01 clinical study for patients with relapsed or refractory multiple myeloma (r/r MM) has restarted patient enrollment. We are planning to share selected updated interim data in 2021."

05
Mar

16
Dec

CLLS Cellectis

$19.29 / -0.9 (-4.46%)

10/15/20 Baird: Cellectis downgraded to Neutral at Baird

10/15/20 Baird: Cellectis downgraded to Neutral from Outperform at Baird

08/19/20: Fly Intel: Top five analyst upgrades

08/19/20 Citi: Cellectis upgraded to Buy from Neutral at Citi

TODAY'S FREE FLY STORIES

Recommendations	Agnico Eagle price target lowered to C$97 from C$98 at National Bank » 10:45 04/23/21 04/23 10:45 04/23/21 10:45 AEM Agnico Eagle $65.86 / -0.27 (-0.41%) National Bank analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options AEM Agnico Eagle $65.86 / -0.27 (-0.41%) 02/16/21 Osisko Gold receives approval for Canadian Malartic Underground construction 02/11/21 Agnico Eagle sees 2021 gold production of 2.05M oz 01/20/21 TMAC receives final court approval for acquisition by Agnico Eagle 01/05/21 Agnico Eagle to acquire TMAC Resources for C$2.20 per share AEM Agnico Eagle $65.86 / -0.27 (-0.41%) 02/23/21 Canaccord Agnico Eagle price target lowered to C$110 from C$115 at Canaccord 02/23/21 Canaccord Agnico Eagle selloff overdone, says Canaccord 02/10/21 JPMorgan Agnico Eagle initiated with a Neutral at JPMorgan 02/02/21 National Bank Agnico Eagle price target lowered to C$109 from C$112 at National Bank AEM Agnico Eagle $65.86 / -0.27 (-0.41%) 02/11/21 Agnico Eagle reports Q4 adjusted EPS 67c, consensus 65c 10/28/20 Agnico Eagle reports Q3 adjusted EPS 78c, consensus 67c 04/30/21 Agnico Eagle - AEM AEM Agnico Eagle $65.86 / -0.27 (-0.41%) 12/16/20 Largest borrow rate increases among liquid names 11/23/20 Largest borrow rate increases among liquid names 11/13/20 Largest borrow rate increases among liquid names
Syndicate	Agiliti indicated to open at $15-$16, IPO priced at $14 » 10:45 04/23/21 04/23 10:45 04/23/21 10:45 AGTI Agiliti $10.51 / + (+0.00%) Agiliti (AGTI) priced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Syndicate AGTI Agiliti $10.51 / + (+0.00%) 10:44 Today Agiliti indicated to open at $15-$16, IPO priced at $14 23 Apr
Options	Futu Holdings call volume above normal and directionally bullish » 10:45 04/23/21 04/23 10:45 04/23/21 10:45 FUTU Futu Holdings $139.99 / +3.99 (+2.93%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate Periodicals On The Fly Options FUTU Futu Holdings $139.99 / +3.99 (+2.93%) 04/19/21 Futu Holdings drops 6% to $167.25 after 9.5M ADS offering 12/08/20 Futu Holdings announces agreement to purchase shares by investment firm FUTU Futu Holdings $139.99 / +3.99 (+2.93%) 03/17/21 Citi Futu Holdings price target lowered to $230.30 from $246.50 at Citi 02/26/21 Citi Futu Holdings price target raised to $246.50 from $119.70 at Citi 02/22/21 86 Research Futu Holdings downgraded to Hold from Buy at 86 Research 02/16/21 Morgan Stanley Futu Holdings initiated with an Overweight at Morgan Stanley 21 Apr 19 Aug FUTU Futu Holdings $139.99 / +3.99 (+2.93%) 02/19/21 China considers loosening restrictions on offshore investments, Bloomberg says FUTU Futu Holdings $139.99 / +3.99 (+2.93%) 04/20/21 Fly Intel: Wall Street's top stories for Tuesday 04/20/21 Fly Intel: Wall Street's top stories at midday 04/19/21 Fly Intel: After-Hours Movers 02/19/21 Fly Intel: Pre-market Movers FUTU Futu Holdings $139.99 / +3.99 (+2.93%) 08:45 Today Largest borrow rate increases among liquid names 04/21/21 Futu Holdings put volume heavy and directionally bearish 04/13/21 Largest borrow rate increases among liquid names 04/01/21 Largest borrow rate increases among liquid names
Hot Stocks	Liberty TripAdvisor Holdings trading halted, volatility trading pause 10:41 04/23/21 04/23 10:41 04/23/21 10:41
Syndicate	Treace Medical indicated to open at $22, IPO priced at $17 » 10:36 04/23/21 04/23 10:36 04/23/21 10:36 TMCI Treace Medical / + Treace Medical Concepts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Syndicate 23 Apr

Hot Stocks	AnaptysBio granted conditional marketing authorization for JEMPERLI » 10:36 04/23/21 04/23 10:36 04/23/21 10:36 ANAB AnaptysBio $23.51 / +0.63 (+2.75%) , GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) AnaptysBio (ANAB)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ANAB GSK ANAB AnaptysBio $23.51 / +0.63 (+2.75%) 04/22/21 FDA approves Jemperli for dMMR endometrial cancer 04/22/21 GlaxoSmithKline confirms FDA approval for Jemperli 04/22/21 FDA grants approval to Jemperli for endometrial cancer with specific biomarker 03/10/21 AnaptysBio rises 8.7% after Ecor1 increased stake to 7.15M shares GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 10:22 Today GlaxoSmithKline reports European Commission approves Jemperli 06:41 Today Roche announces FDA approval of VENTANA MMR RxDx panel 04/22/21 GlaxoSmithKline announces FDA approval of JEMPERLI 04/22/21 FDA approves Jemperli for dMMR endometrial cancer ANAB GSK ANAB AnaptysBio $23.51 / +0.63 (+2.75%) 03/16/21 Fly Intel: Top five analyst upgrades 03/16/21 Truist AnaptysBio upgraded to Buy from Hold at Truist 03/16/21 Truist AnaptysBio upgraded to Buy from Hold at Truist 03/09/21 Wedbush AnaptysBio downgraded to Neutral at Wedbush GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 04/20/21 Morgan Stanley GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley 04/20/21 UBS GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS 04/20/21 Citi GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi 03/23/21 Fly Intel: Top five analyst downgrades ANAB GSK ANAB AnaptysBio $23.51 / +0.63 (+2.75%) 02/25/21 AnaptysBio reports Q4 EPS $1.20, consensus $1.39 11/04/20 AnaptysBio reports Q3 EPS (87c), consensus (72c) GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago GSK GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 04/15/21 Activist Elliott builds 'multibillion-pound' stake in GlaxoSmithKline, FT says 02/09/21 Teva wins new hearing on $235M GSK patent verdict, Bloomberg reports 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports ANAB GSK ANAB AnaptysBio $23.51 / +0.63 (+2.75%) 03/08/21 Fly Intel: Wall Street's top stories for Monday 03/08/21 Fly Intel: Wall Street's top stories at midday 02/11/21 Zillow, Bed Bath & Beyond upgrades among today's top calls on Wall Street GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 03/11/21 Fly Intel: Wall Street's top stories for Thursday 03/11/21 Fly Intel: Wall Street's top stories at midday 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 05/24/21 Global Healthcare Virtual Conference 2021 04/28/21 GlaxoSmithKline - GSK GSK GSK GlaxoSmithKline $37.58 / -0.1 (-0.27%) 04/15/21 Unusually active option classes on open April 15th
Options	Rite Aid put volume heavy and directionally bearish » 10:35 04/23/21 04/23 10:35 04/23/21 10:35 RAD Rite Aid $18.33 / +0.14 (+0.77%) Bearish flow noted in… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options RAD Rite Aid $18.33 / +0.14 (+0.77%) 03/25/21 Rite Aid falls -22.7% 03/25/21 Rite Aid falls -17.6% 03/24/21 Rite Aid narrows FY21 net loss view to ($100M) to ($90M) from ($114M) to ($89M) 03/24/21 Rite Aid falls over 14% below $20 after FY21 guidance cut RAD Rite Aid $18.33 / +0.14 (+0.77%) 03/25/21 Deutsche Bank Rite Aid price target raised to $27 from $17 at Deutsche Bank 03/25/21 Deutsche Bank Rite Aid named short-term buy idea at Deutsche Bank 12/18/20 Deutsche Bank Rite Aid price target raised to $17 from $9 at Deutsche Bank 11/17/20 Oppenheimer Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer RAD Rite Aid $18.33 / +0.14 (+0.77%) 04/15/21 Rite Aid sees Q1 revenue $6.1B-$6.3B, consensus $6.05B 04/15/21 Rite Aid reports Q4 EPS (78c), consensus (76c) 03/24/21 Rite Aid sees FY21 revenue approx. $24.0B, consensus $24.07B 12/17/20 Rite Aid raises FY21 adjusted EPS view to 45c-85c from (67c)-9c, consensus (9c) RAD Rite Aid $18.33 / +0.14 (+0.77%) 04/15/21 Fly Intel: Pre-market Movers 03/25/21 Fly Intel: Wall Street's Top Stories for Thursday 03/25/21 Fly Intel: Pre-market Movers 03/24/21 Fly Intel: After-Hours Movers RAD Rite Aid $18.33 / +0.14 (+0.77%) 04/20/21 Rite Aid put volume heavy and directionally bearish 03/31/21 Rite Aid call volume above normal and directionally bullish 03/26/21 Rite Aid call volume above normal and directionally bullish 03/16/21 Rite Aid call volume above normal and directionally bullish
General news	Oil Action: WTI crude » 10:35 04/23/21 04/23 10:35 04/23/21 10:35 $ECON Economic Data / + Oil Action: WTI crude… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><<
Recommendations	Inter Pipeline price target raised to C$18 from C$17.50 at Scotiabank » 10:34 04/23/21 04/23 10:34 04/23/21 10:34 IPPLF Inter Pipeline $14.50 / +0.2918 (+2.05%) Scotiabank analyst Robert… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research IPPLF Inter Pipeline $14.50 / +0.2918 (+2.05%) 03/11/21 Brookfield Infrastructure comments on Inter Pipeline directors' circular IPPLF Inter Pipeline $14.50 / +0.2918 (+2.05%) 07:39 Today Stifel Inter Pipeline downgraded to Hold at Stifel on strategic review uncertainty 04/22/21 Stifel Inter Pipeline downgraded to Hold from Buy at Stifel 04/06/21 Stifel Inter Pipeline price target raised to C$20.50 from C$20 at Stifel 02/24/21 National Bank Inter Pipeline price target raised to C$18 from C$15 at National Bank
Recommendations	CGI Inc. price target raised to C$112 from C$106 at Scotiabank » 10:34 04/23/21 04/23 10:34 04/23/21 10:34 GIB CGI Inc. $85.50 / -0.02 (-0.02%) Scotiabank analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events GIB CGI Inc. $85.50 / -0.02 (-0.02%) 03/30/21 CGI Inc. selected for Federal Reserve Bank's FedNow service pilot 03/23/21 CGI creates 600 jobs at Lafayette delivery center, expects to reach 800 by 2023 03/11/21 CGI Inc. awarded contract by Bavarian State Ministry of Justice 02/26/21 CGI Inc. announces IT delivery center in Knoxville, Tennessee GIB CGI Inc. $85.50 / -0.02 (-0.02%) 04/12/21 Societe Generale CGI Inc. upgraded to Hold from Sell at Societe Generale 03/23/21 Desjardins CGI Inc. resumed with a Buy at Desjardins 03/04/21 Edward Jones CGI Inc. upgraded to Buy from Hold at Edward Jones 02/01/21 Barclays CGI Inc. price target raised to $89 from $80 at Barclays GIB CGI Inc. $85.50 / -0.02 (-0.02%) 01/27/21 CGI Inc. reports Q1 ex-items EPS C$1.33 vs. C$1.23 last year 11/11/20 CGI Inc. reports Q4 EPS C$1.22, vs. C$1.21 last year 04/28/21 CGI Inc. - GIB

Syndicate	Rain Therapeutics indicated to open at $27, IPO priced at $17 » 10:33 04/23/21 04/23 10:33 04/23/21 10:33 RAIN Rain Therapeutics / + Rain Therapeutics (RAIN)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Syndicate 23 Apr
Syndicate	Latham Group indicated to open at $22, IPO priced at $19 » 10:32 04/23/21 04/23 10:32 04/23/21 10:32 SWIM Latham Group / + Latham Group (SWIM)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Syndicate On The Fly 23 Apr SWIM Latham Group / + 04/17/21 Opening Day: Coinbase soars in market debut 04/10/21 Opening Day: Phone maker UTime soars in public debut 04/03/21 Opening Day: Softbank-backed Compass raises $450M in IPO
Options	Bristol Myers Squibb call volume above normal and directionally bullish » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) Bullish option flow… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 10:03 Today Bristol-Myers says Phase 3 trials of deucravacitinib met co-primary endpoints 06:54 Today Bristol-Myers announces EMA's CHMP recommends approval of Onureg in Europe 06:47 Today Bristol-Myers announces EMA's CHMP recommends approval of Opdivo 04/16/21 Bristol-Myers confirms FDA approves Opdivo combo for gastric cancer BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/21/21 Citi Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data 04/21/21 Citi Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy 04/13/21 Truist Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility 04/13/21 Truist Bristol-Myers upgraded to Buy from Hold at Truist BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/01/21 Accidental disclosure show Bristol-Myers, I.R.S. $1B tax fight, NY Times reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/13/21 FedEx, Booking Holdings upgrades among today's top calls on Wall Street 03/29/21 Fly Intel: Pre-market Movers 02/09/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks 11:00 Today Pharmaceuticals 12:00 Today Biotechnology 04/29/21 Bristol-Myers - BMY 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 05/20/21 PDUFA Date for CM-577 - Opdivo 05/25/21 PDUFA Date for CM-649 Opdivo+ Yervoy or Chemo 05/30/21 PDUFA Date for Zeposia (Ozanimod) 01/28/22 PDUFA Date for Mavacamten 05/04/21 Bristol Myers Squibb Co BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/07/21 Unusually active option classes on open April 7th 01/20/21 Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish
Conference/Events	Cowen pharmaceuticals analysts to hold analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) Pharmaceuticals Analysts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 10:03 Today Bristol-Myers says Phase 3 trials of deucravacitinib met co-primary endpoints 06:54 Today Bristol-Myers announces EMA's CHMP recommends approval of Onureg in Europe 06:47 Today Bristol-Myers announces EMA's CHMP recommends approval of Opdivo 04/16/21 Bristol-Myers confirms FDA approves Opdivo combo for gastric cancer BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/21/21 Citi Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data 04/21/21 Citi Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy 04/13/21 Truist Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility 04/13/21 Truist Bristol-Myers upgraded to Buy from Hold at Truist BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 03/04/21 Repare Therapeutics reports Q4 EPS ($2.66), consensus (39c) 02/24/21 CytomX Therapeutics reports Q4 revenue $16.4M, consensus $15.4M 02/04/21 Bristol-Myers boosts FY21 adjusted EPS view to $7.35-$7.55 from $7.15-$7.45 02/04/21 Bristol-Myers reports Q4 adjusted EPS $1.46, consensus $1.41 BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/01/21 Accidental disclosure show Bristol-Myers, I.R.S. $1B tax fight, NY Times reports 02/15/21 Bristol-Myers, Sanofi to pay $834M over Plavix, Bloomberg reports 12/23/20 Judge rules against White House drug pricing rule, Reuters says 11/23/20 EU seeks easier access to generic medicines, Reuters says BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/13/21 FedEx, Booking Holdings upgrades among today's top calls on Wall Street 03/29/21 Fly Intel: Pre-market Movers 02/09/21 Fly Intel: Pre-market Movers 12/26/20 Week in review: How Trump's policies moved stocks 11:00 Today Pharmaceuticals 12:00 Today Biotechnology 04/29/21 Bristol-Myers - BMY 04/29/21 Oncologic Drugs Advisory Committee Virtual Meeting 05/20/21 PDUFA Date for CM-577 - Opdivo 05/25/21 PDUFA Date for CM-649 Opdivo+ Yervoy or Chemo 05/30/21 PDUFA Date for Zeposia (Ozanimod) 01/28/22 PDUFA Date for Mavacamten 05/04/21 Bristol Myers Squibb Co BMY Bristol-Myers $66.89 / +0.57 (+0.86%) 04/07/21 Unusually active option classes on open April 7th 01/20/21 Unusually active option classes on open January 20th 01/11/21 Unusually active option classes on open January 11th 01/05/21 Bristol Myers Squibb call volume above normal and directionally bullish
Conference/Events	Cantor Fitzgerald biopharma analysts hold an analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Large Cap & Biopharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial

Conference/Events	UBS technology analyst to hold an analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Technology Analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Conference/Events	Truist digital advertising analysts to hold analyst/industry conference call » 10:25 04/23/21 04/23 10:25 04/23/21 10:25 Digital Ad Analysts,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Allegiance Bancshares approves stock repurchase authorization up to 1M shares » 10:24 04/23/21 04/23 10:24 04/23/21 10:24 ABTX Allegiance Bancshares $39.02 / + (+0.00%) On April 22, 2021, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10:23 Today Allegiance Bancshares appoints Raimundo Riojas to board of directors 01/28/21 Allegiance Bancshares raises quarterly dividend 20% to 12c per share ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10/02/20 Janney Montgomery Scott Allegiance Bancshares initiated with a Neutral at Janney Montgomery Scott ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares reports Q4 EPS 77c, consensus 71c 10/29/20 Allegiance Bancshares reports Q3 EPS 79c, consensus 52c 04/29/21 Allegiance Bancshares - ABTX
Recommendations	WeCommerce price target lowered to C$23 from C$26 at TD Securities » 10:23 04/23/21 04/23 10:23 04/23/21 10:23 WECMF WeCommerce $14.79 / +0.4312 (+3.00%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial
Hot Stocks	Allegiance Bancshares appoints Raimundo Riojas to board of directors » 10:23 04/23/21 04/23 10:23 04/23/21 10:23 ABTX Allegiance Bancshares $39.02 / + (+0.00%) Allegiance Bancshares… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares raises quarterly dividend 20% to 12c per share ABTX Allegiance Bancshares $39.02 / + (+0.00%) 10/02/20 Janney Montgomery Scott Allegiance Bancshares initiated with a Neutral at Janney Montgomery Scott ABTX Allegiance Bancshares $39.02 / + (+0.00%) 01/28/21 Allegiance Bancshares reports Q4 EPS 77c, consensus 71c 10/29/20 Allegiance Bancshares reports Q3 EPS 79c, consensus 52c 04/29/21 Allegiance Bancshares - ABTX

Recommendations	Intact Financial price target raised to C$185 from C$175 at TD Securities » 10:22 04/23/21 04/23 10:22 04/23/21 10:22 IFCZF Intact Financial $130.32 / -0.03 (-0.02%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research IFCZF Intact Financial $130.32 / -0.03 (-0.02%) 02/12/21 Desjardins Intact Financial price target raised to C$175 from C$170 at Desjardins 02/10/21 National Bank Intact Financial price target raised to C$200 from C$192 at National Bank 02/10/21 TD Securities Intact Financial price target raised to C$175 from C$170 at TD Securities 12/08/20 Scotiabank Intact Financial price target raised to C$175 from C$166 at Scotiabank
Hot Stocks	GlaxoSmithKline reports European Commission approves Jemperli » 10:22 04/23/21 04/23 10:22 04/23/21 10:22 GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) GlaxoSmithKline announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 06:41 Today Roche announces FDA approval of VENTANA MMR RxDx panel 04/22/21 GlaxoSmithKline announces FDA approval of JEMPERLI 04/22/21 FDA approves Jemperli for dMMR endometrial cancer 04/22/21 GlaxoSmithKline confirms FDA approval for Jemperli GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/20/21 Morgan Stanley GlaxoSmithKline price target lowered to 1,550 GBp at Morgan Stanley 04/20/21 UBS GlaxoSmithKline price target raised to 1,360 GBp from 1,320 GBp at UBS 04/20/21 Citi GlaxoSmithKline collaboration with Merck would be 'win-win,' says Citi 03/23/21 Fly Intel: Top five analyst downgrades GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 02/03/21 GlaxoSmithKline reports Q4 adjusted EPS 23.3p vs. 24.8p a year ago 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/15/21 Activist Elliott builds 'multibillion-pound' stake in GlaxoSmithKline, FT says 02/09/21 Teva wins new hearing on $235M GSK patent verdict, Bloomberg reports 01/12/21 GSK looks to double blockbusters in portfolio by 2026, Bloomberg says 12/31/20 Drugmakers to hike U.S. prices on over 200 drugs, Reuters reports GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 03/11/21 Fly Intel: Wall Street's top stories for Thursday 03/11/21 Fly Intel: Wall Street's top stories at midday 02/22/21 Fly Intel: Wall Street's top stories for Monday 02/22/21 Fly Intel: Wall Street's top stories at midday 05/24/21 Global Healthcare Virtual Conference 2021 04/28/21 GlaxoSmithKline - GSK GSK GlaxoSmithKline $37.65 / -0.03 (-0.08%) 04/15/21 Unusually active option classes on open April 15th
Recommendations	Walmart+ members may have declined to 11.1M in March, says Cowen » 10:21 04/23/21 04/23 10:21 04/23/21 10:21 WMT Walmart $139.75 / +0.08 (+0.06%) Cowen analyst Oliver Chen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WMT Walmart $139.75 / +0.08 (+0.06%) 04/20/21 Velodyne Lidar signs multi-year sales agreement with Gatik 04/20/21 U.K.'s CMA: Bellis' purchase of Asda raises some competition concerns 04/19/21 Walmart adds the BinaxNOW COVID-19 Antigen Self Test 04/19/21 Abbott begins shipping BinaxNOW COVID-19 Ag Self Test to retailers WMT Walmart $139.75 / +0.08 (+0.06%) 04/06/21 Morgan Stanley Walmart+ membership 'seems to have stagnated,' says Morgan Stanley 03/16/21 MKM Partners Walmart price target lowered to $141 from $154 at MKM Partners 02/23/21 Evercore ISI Walmart accelerating change with investments, says Evercore ISI 02/19/21 Morgan Stanley Walmart terminal value rising with investments, says Morgan Stanley WMT Walmart $139.75 / +0.08 (+0.06%) 02/18/21 Walmart reports Q4 adjusted EPS $1.39, consensus $1.51 02/17/21 Notable companies reporting before tomorrow's open 02/17/21 Notable companies reporting before tomorrow's open 11/17/20 Walmart reports Q3 adjusted EPS $1.34, consensus $1.18 WMT Walmart $139.75 / +0.08 (+0.06%) 04/21/21 Walmart phasing out automated pickup towers, WSJ reports 04/13/21 Walmart compliance chief leaving company, WSJ reports 04/13/21 Walmart chief ethics and compliance officer leaving company, WSJ says 04/09/21 McDonald's closing 'hundreds' of restaurants inside Walmart, WSJ reports WMT Walmart $139.75 / +0.08 (+0.06%) 04/19/21 Charged: Walmart invests in GM-backed self-driving company Cruise 04/19/21 Vizio rises as Wall Street analysts roll out bullish coverage 03/17/21 Street Fight: Analysts diverge on Plug following financial restatement news 03/10/21 Fly Intel: What to watch in Oracle's earnings report 06/02/21 Wal-Mart Stores, Inc. WMT Walmart $139.75 / +0.08 (+0.06%) 04/20/21 Wal-Mart call volume above normal and directionally bullish 04/06/21 Wal-Mart call volume above normal and directionally bullish 04/05/21 Unusually active option classes on open April 5th 03/29/21 Unusually active option classes on open March 29th
Recommendations	Well Health Technologies price target raised to C$10.50 from C$10 at TD Securities » 10:19 04/23/21 04/23 10:19 04/23/21 10:19 WLYYF Well Health Technologies $5.50 / -0.1591 (-2.81%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Street Research WLYYF Well Health Technologies $5.50 / -0.1591 (-2.81%) 03/19/21 TD Securities Well Health price target lowered to C$10 from C$11 at TD Securities 03/10/21 Desjardins Well Health Technologies upgraded to Buy from Hold at Desjardins 02/18/21 Stifel Well Health Technologies price target raised to C$13.50 from C$10 at Stifel 02/10/21 Desjardins Well Health Technologies downgraded to Hold from Buy at Desjardins
Recommendations	Superior Plus price target raised to C$16.50 from C$15.50 at TD Securities » 10:19 04/23/21 04/23 10:19 04/23/21 10:19 SUUIF Superior Plus $11.79 / -0.0109 (-0.09%) TD Securities analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Street Research SUUIF Superior Plus $11.79 / -0.0109 (-0.09%) 05:00 Today Industrial Alliance Superior Plus downgraded to Hold from Buy at Industrial Alliance 02/22/21 BMO Capital Superior Plus price target raised to C$12.50 from C$12 at BMO Capital 02/19/21 TD Securities Superior Plus price target raised to C$15.50 from C$14.50 at TD Securities 02/19/21 Scotiabank Superior Plus price target raised to C$15 from C$13 at Scotiabank

Events

Earnings calls, analyst events, roadshows and more

NBHC
Today at 11:00

National Bank - NBHC Conference Calls
GBCI
Today at 11:00

Glacier Bancorp - GBCI Conference Calls
OZK
Today at 11:00

Bank OZK - OZK Conference Calls
AZZ
Today at 11:00

AZZ Inc. - AZZ Conference Calls
EIG
Today at 11:00

Employers Holdings - EIG Conference Calls
NGA
Today at 11:00

NORTHERN GENESIS ACQUISITION Firm Sponsored Meetings
SNCA
Today at 11:00

Seneca Biopharma Inc Firm Sponsored Meetings
Today at 11:00

Communications Technology Industry Meetings
Today at 11:00

Digital Advertising Industry Meetings
Today at 11:00

Biopharma & Medical Devices Industry Meetings

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	CHWY X CHWY Chewy Block Trade Managers: Morgan Stanley Priced at: $82.50 6.1M Shares IFBD X IFBD Infobird IPO Managers: WestPark Capital Priced at: $4.00 6.25M Shares
Tues	DV X DV DoubleVerify IPO Managers: Goldman Sachs & JPMorgan, Barclays, RBC Capital, Truist, William Blair, KeyBanc, Canaccord, JMP Securities, Needham, Loop Capital, Capital One Priced at: $27.00 13.3M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PATH X PATH UiPath IPO Managers: Morgan Stanley & JPMorgan, BofA, Credit Suisse, Barclays, Wells Fargo, SMBC Nikko, BMO Capital, MIZU, KeyBanc, TD Securities, Truist, Cowen, Evercore ISI, Macquarie, Nomura, RBC Capital, Canaccord, DA Davidson, Oppenheimer, Needham Priced at: $56.00 23.89M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SKYT X SKYT SkyWater Technology IPO Managers: Jefferies & Cowen, Piper Sandler Priced at: $14.00 6.96M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TRKA X TRKA Troika Media IPO Managers: Kingswood Priced at: $4.15 5.78M Shares FUTU X FUTU Futu Holdings Secondary Managers: BofA & Haitong Priced at: $130.00 9.5M Shares ZLAB X ZLAB Zai Lab Secondary Managers: JPMorgan, Goldman Sachs, Jefferies, Citi, SVB Leerink & Guggenheim Priced at: $150.00 4.78M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NOTV X NOTV Inotiv Spot Secondary Managers: Colliers Priced at: $17.00 2.647M Shares
Wed	KNBE X KNBE KnowBe4 IPO Managers: Morgan Stanley, Goldman Sachs, BofA & KKR Priced at: $16.00 9.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NPCE X NPCE NeuroPace IPO Managers: JPMorgan & Morgan Stanley, Wells Fargo, SVB Leerink Priced at: $17.00 6M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ZY X ZY Zymergen IPO Managers: JPMorgan & Goldman Sachs, BofA, UBS, LAZA Priced at: $31.00 16.13M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EOLS X EOLS Evolus Spot Secondary Managers: SVB Leerink, Stifel & Cantor Fitzgerald Priced at: $9.50 9M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NBSE X NBSE NeuBase Therapeutics Spot Secondary Managers: RBC Capital, Oppenheimer & Chardan, National Securities Priced at: $5.00 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	AGTI X AGTI Agiliti IPO Managers: BofA, Goldman Sachs, Morgan Stanley & BMO Capital, Citi, JEFF< UBSW, KeyBanc, Raymond James, MUFG, SMBC Nikko, MISC, SIEB Priced at: $14.00 26.316M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial IMPL X IMPL Impel NeuroPharma IPO Managers: Cowen & Guggenheim, Wedbush Priced at: $15.00 5.33M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial RAIN X RAIN Rain Therapeutics IPO Managers: Goldman Sachs, Citi, Piper Sandler & Guggenheim Priced at: $17.00 7.353M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SWIM X SWIM Latham Group IPO Managers: Barclays, BofA, Morgan Stanley & Goldman Sachs, Nomura, William Blair, Baird, KeyBanc, Truist Priced at: $19.00 20M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TMCI X TMCI Treace Medical IPO Managers: JPMorgan & Morgan Stanley, SVB Leerink, Stifel Priced at: $17.00 11.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EDAP X EDAP EDAP TMS Spot Secondary Managers: Piper Sandler Priced at: $6.75 4.15M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Cellectis reports Q4 adjusted EPS (88c), consensus (78c)

TODAY'S FREE FLY STORIES

Get Full Fly Access